ARIMIDEX: A potent and selective aromatase inhibitor for the treatment of advanced breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 61, Issue 3-6, 1997, Pages 145-149

  Buzdar, Aman U ^a   Jonat, Walter ^b   Howell, Anthony ^c   Plourde, Paul V ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CORTICOTROPIN; ESTRADIOL; MEGESTROL ACETATE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; WEIGHT GAIN;

EID: 0031123897     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00247-6     Document Type: Conference Paper

References (11)

1. Lipton A., Harvey H.A., Santen R.J., Boucher A., White D., Bernath A., Dixon R., Richards G., Shafik A. Randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 42:1982;3434-3436.
2. Coombes R.C., Powles T.J., Easton D., Chilvers C., Ford H.T., Smith I.E., McKinna A., White H., Bradbeer J., Yarnold J., Nash A., Bettelheim R., Dowsett M., Gazet J.-C. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res. 47:1987;2496-2499.
3. Henderson C., Hayes D.F., Come S., Harris J.R., Canellos G. New agents and new medical treatments for advanced breast cancer. Semin. Oncol. 14:1987;34-64.
4. Miller W.R. Aromatase inhibitors - where are we now? Br. J. Cancer. 73:1996;415-417.
5. Plourde P.V., Dyroff M., Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat. 30:1994;103-111.
6. Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L., Eiermann W., Wolter J.M., Azab M., Webster A., Plourde P.V. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J. Clin. Oncol. 14:1996;2000-2011.
7. Demers L.M. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat. 30:1994;95-102.
8. Dowsett M., Godd P.E., Powles T.J., Hutchinson G., Brodie A.M.H., Jeffcoate S.L., Coombes R.C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 47:1987;1957-1961.
9. Jonat W., Howell A., Blomqvist C., Eiermann W., Winblad G., Tyrrell C., Mauriac L., Roche H., Lundgren S., Hellmund R. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer. 32A:1996;404-412.
10. Hayward J.L., Carbone P.P., Heuson J.-C., Kumaoka S., Segaloff A., Rubens R.D. Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer. 13:1977;89-94.
11. Buzdar A.U., Howell A., Jones S., Blomqvist C., Vogel C., Eiermann W., Wolters J., Mauriac L., Eisenberg P., Jonat W., Plourde P., Azab M. Prolonged exposure confirms a favorable tolerability profile of Arimidex (anastrozole) as compared to megestrol acetate from two large randomized trials in postmenopausal women with advanced breast cancer. Vol. 15 Proceedings of the 32nd Annual American Society of Clinical Oncology. 1996;109. (Abstract 100).